Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate whether a semi-quantitative interpretation using the liver SUVmax as reference can better interpret 18F-FDG PET/CT and predict disease progression during chemotherapy or survival in PTCL.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
In this study investigators develope a semi-quantitative interpretation using the liver SUVmax as reference to interpret 18F-FDG PET/CT. Positive lesions in PET were indicated as SUVmax of residues higher than the threshold or new 18F-FDG avid lesions. Investigators compare the prognostic accuracy of the liver SUVmax-based criteria with the 5-PS criteria and ΔSUVmax interpretation with respect to predicting disease progression during chemotherapy or survival in PTCL. Furthermore,investigators improve the prognostic ability of interim PET/CT by comparing the results to the clinical prognostic factors.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: PTCL patients with 18F-FDG PET/CT 18F-FDG PET/CT scans is to be evaluated using liver SUVmax-based criteria, Deauville 5-point criteria and reduction of SUVmax criteria |
Device: 18F-FDG PET/CT
18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
|
Outcome Measures
Primary Outcome Measures
- Change from baseline in summed standardized uptake value (SUVmax) of lesion after 2 or 4 cycles [baseline(diagnosed by pathology and before chemotherapy) and 2 or 4 cycles after starting chemotherapy (each cycle 21days)]
Secondary Outcome Measures
- 3 year progression-free survival [up to 3 years after initial diagnosis]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
newly diagnosed PTCL
-
treated using an anthracycline-containing regimen
-
minimal follow-up at 6 months after the completion of first-line treatment
-
complete medical history and clinicopathological data
Exclusion Criteria:
-
secondary malignant disease
-
serious infection or inflammation (e.g., HIV)
-
primary central nervous system lymphoma
-
hepatic or renal dysfunction.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Peking University Cancer Hospital | Beijing | Beijing | China | 100142 |
Sponsors and Collaborators
- Peking University Cancer Hospital & Institute
- Beijing Municipal Administration of Hospitals
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- XW-PTCL-001